Radiopharmaceutical manufacturing has to satisfy three demanding regulatory dimensions at once: sterile production, total quality management, and radiation safety. CellAuto’s “three swords” of nuclear-medicine automation — the Fully-Automatic Dispensing System, the Intelligent Waste Treatment System, and the Lead-Pot Circulation System — address all three as one integrated, intelligent solution.<\/p>\n
Regulatory challenge:<\/strong> The revised Annex 1 raises sterility assurance to an unprecedented level, stressing a “built-in” contamination control strategy (CCS), requiring human intervention to be minimised, and demanding continuous, controllable monitoring of the environment and the process. The traditional model of manual operation inside a hot cell faces major challenges in intervention frequency, environmental control and data reliability.<\/p>\n Role:<\/strong> completes the core filling operation inside a fully-closed hot cell or RABS (restricted access barrier system), fundamentally eliminating the main microbial and particulate contamination risks introduced by operators.<\/p>\n Value:<\/strong> makes the line natively compliant with Annex 1’s high-pass-rate requirements for aseptic process simulation, and provides a solid process basis for “parametric release” — the core of a next-generation, natively-compliant aseptic line.<\/p>\n Role:<\/strong> automatically and in a closed manner collects, sorts and processes the radioactive liquid, gaseous and solid waste generated during production.<\/p>\n Value:<\/strong> upgrades contamination control from “after-the-fact environmental wiping” to “real-time process monitoring and automatic interception”, forming a key part of the CCS and directly answering Annex 1’s expectation of continuous dynamic monitoring of critical areas.<\/p>\n Regulatory challenge:<\/strong> EU GMP requires a quality management system covering the whole lifecycle, built around data integrity (the ALCOA+ principles), process consistency and traceability. The traditional model, heavily reliant on manual records and experience-based judgement, is a major source of data errors, deviations and loss of traceability.<\/p>\n Role:<\/strong> all three systems automatically record every key operating parameter (dispensing volume and activity, radioactivity concentration of waste, and the route and timing of lead-pot transfers), uploading the data directly to the MES (manufacturing execution system), tamper-proof and traceable.<\/p>\n Value:<\/strong> fully meets data-integrity requirements and provides an electronic chain of evidence for batch records, deviation investigations and release decisions, greatly reducing compliance-audit risk.<\/p>\n Role:<\/strong> replaces variable manual steps with pre-set, validated automated programs.<\/p>\n Value:<\/strong> ensures that the same product made by different shifts on different days has highly consistent quality attributes, markedly reducing batch-to-batch variation — a prerequisite for sustained process validation and continued process verification (CPV).<\/p>\n Role:<\/strong> through RFID \/ QR codes in the lead-pot circulation system, the physical flow is bound to the information flow, achieving full-chain tracking from synthesis to dispensing to interim storage.<\/p>\n Value:<\/strong> delivers efficient traceability far beyond paper records; if a problem arises, affected materials and products can be located within minutes, greatly improving quality control and recall efficiency.<\/p>\n Regulatory challenge:<\/strong> Standards such as USP <825> place particular emphasis on protecting operators and the public from radiation while ensuring product quality, and set extremely strict requirements for the dose accuracy of individualised administration. The traditional model has bottlenecks in both radiation protection and dose accuracy.<\/p>\n Role:<\/strong> the dispensing and waste systems completely isolate personnel from the highest-exposure dispensing and waste-handling stations, while the lead-pot circulation system uses AGVs instead of manual handling of heavy lead pots, preventing physical strain and accidental exposure during transfer.<\/p>\n Value:<\/strong> systematically achieves optimised radiation protection (ALARA), reducing occupational exposure to the lowest reasonably achievable level, meeting strict radiation-safety regulations and improving staff safety and corporate social responsibility.<\/p>\n Role:<\/strong> the fully-automatic dispensing system automatically calculates and dispenses a specific activity of solution to sub-microlitre precision according to each patient’s prescription.<\/p>\n Value:<\/strong> ensures the treatment dose is delivered accurately to the patient — the ultimate safeguard of efficacy and safety for radiopharmaceuticals, especially therapeutic nuclides such as Lu-177 — directly meeting USP <825>’s core requirement for dispensing accuracy.<\/p>\n Role:<\/strong> the system can apply stricter sealing and monitoring procedures for alpha nuclides (such as Ac-225); the waste system processes waste by nuclide; and the lead-pot circulation system intelligently schedules different nuclide materials to prevent cross-contamination.<\/p>\n Value:<\/strong> provides safe, compliant engineering controls for handling a new generation of higher-risk nuclides, supporting companies as they plan future pipelines.<\/p>\n CellAuto’s “three swords” of nuclear-medicine automation are not isolated equipment upgrades, but a systematic engineering solution to the core bottlenecks of radiopharmaceutical industrialisation. They build sterility assurance in by design (Annex 1), reinforce quality management in process (EU GMP), and strengthen dedicated safety and precision in operation (USP <825>).<\/p>\n In doing so, they transform the traditional “human-experience-centred, compliance-patched” production model into a modern industrial model that is “automation-system-centred, with native compliance as its foundation” — not only the answer to today’s problem of hot cells “stuck twenty years ago”, but a key infrastructure upgrade as the industry moves toward large-scale, global, high-quality development.<\/p>\n","protected":false},"excerpt":{"rendered":" Radiopharmaceutical manufacturing has to satisfy three demanding regulatory dimensions at once: sterile production, total quality management, and radiation safety. CellAuto’s “three swords” of nuclear-medicine automation — the Fully-Automatic Dispensing System, the Intelligent [\u2026]<\/span><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[39],"tags":[],"_links":{"self":[{"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/posts\/3754"}],"collection":[{"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/comments?post=3754"}],"version-history":[{"count":1,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/posts\/3754\/revisions"}],"predecessor-version":[{"id":3843,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/posts\/3754\/revisions\/3843"}],"wp:attachment":[{"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/media?parent=3754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/categories?post=3754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cellauto.com\/cellauto\/wp-json\/wp\/v2\/tags?post=3754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}1. Fully-Automatic Dispensing System<\/h3>\n
2. Intelligent Waste Treatment System<\/h3>\n
Dimension 2: Reinforcing the foundation of total quality management (benchmarked against the overall EU GMP framework)<\/h2>\n
1. End-to-end data automation<\/h3>\n
2. Process standardisation and consistency<\/h3>\n
3. Full traceability of materials and products<\/h3>\n
Dimension 3: Strengthening radiopharmaceutical-specific operations and safety (benchmarked against USP <825> and radiation-safety regulations)<\/h2>\n
1. Optimal personnel radiation protection (the ALARA principle)<\/h3>\n
2. Precise and reliable individualised dosing<\/h3>\n
3. Dedicated management of multiple and high-risk nuclides<\/h3>\n
Summary<\/h2>\n